BURLINGTON, Mass., March 12, 2026 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will participate in The Stifel 2026 Virtual CNS Forum being held March 17-18, 2026.
|
The Stifel 2026 Virtual CNS Forum |
|
|
Format: |
Company presentation |
|
Day/Time: |
Wednesday, March 18 at 8.30 AM ET |
|
Webcast: |
Webcast Link: |
|
https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYEQLLU6kp2AWRS6bu |
|
The Stifel 2026 Virtual CNS Forum
Wednesday, March 18 at 8.30 AM ET
https://event.summitcast.com/view/4Ggc9Rmi4GQpDPGZwDp8g8/DdYPDYEQLLU6kp2AWRS6bu
If you are interested in a virtual meeting with the Minerva team during the conference, please reach out to your Stifel representative.
A replay of the presentation will be available on the Company’s Investors & Media Events and Presentations webpage for ninety days following the event.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva is initiating a confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia. For more information, please visit the Company’s website.
Contacts:Investor inquiries:
Frederick AhlholmChief Financial OfficerMinerva Neurosciences, [email protected]
Corey Davis, Ph.D.LifeSci Advisors, [email protected]